Cargando…
A Novel MAX Gene Mutation Variant in a Patient With Multiple and “Composite” Neuroendocrine–Neuroblastic Tumors
Introduction: Pheochromocytomas (PCCs), paragangliomas (PGLs), ganglioneuroblastomas (GNBs), and ganglioneuromas (GNs) are neuroendocrine neoplasms (NENs) that were thought to share a common embryologic origin from neural crest cells. However, they rarely occur concurrently and recurrently. We descr...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249266/ https://www.ncbi.nlm.nih.gov/pubmed/32508744 http://dx.doi.org/10.3389/fendo.2020.00234 |
_version_ | 1783538558571642880 |
---|---|
author | Pozza, Carlotta Sesti, Franz Di Dato, Carla Sbardella, Emilia Pofi, Riccardo Schiavi, Francesca Bonifacio, Vincenzo Isidori, Andrea M. Faggiano, Antongiulio Lenzi, Andrea Giannetta, Elisa |
author_facet | Pozza, Carlotta Sesti, Franz Di Dato, Carla Sbardella, Emilia Pofi, Riccardo Schiavi, Francesca Bonifacio, Vincenzo Isidori, Andrea M. Faggiano, Antongiulio Lenzi, Andrea Giannetta, Elisa |
author_sort | Pozza, Carlotta |
collection | PubMed |
description | Introduction: Pheochromocytomas (PCCs), paragangliomas (PGLs), ganglioneuroblastomas (GNBs), and ganglioneuromas (GNs) are neuroendocrine neoplasms (NENs) that were thought to share a common embryologic origin from neural crest cells. However, they rarely occur concurrently and recurrently. We describe the case of a 40-years-old woman with “composite PCC-GN” and multiple NENs and neuroblastic tumors. Case presentation: The patient was first referred to our department at the age of 15 years for paroxysmal hypertension, headache, sweating, and watery diarrhea. Her personal history included the diagnosis of a pelvic GNB with lumbar–aortic lymph node metastases at 11 months. Her family history was positive for cerebral glioblastoma multiforme (father). An abdominal ultrasound showed a right adrenal mass that histologically was a “composite adrenal PCC-GN.” The symptoms disappeared after surgery. At the age of 20 years, the symptoms returned: computed tomography (CT) and 131I-metaiodobenzylguanidine (MIBG) scintigraphy showed an inter-aortocaval mass, found histologically to be an inter-aortocaval PGL. Her symptoms reappeared again at 28 years: CT and magnetic resonance imaging revealed four left adrenal gland nodules, found histologically to be multifocal PCCs with some atypia. Genetic screening for VHL, RET, NF1, Tp53, SDHD, SDHB, SDHC, SDHAF2, SDHAF3, SDHA, and TMEM127 was negative. Mutational analysis of the MAX gene revealed the presence of a novel heterozygous variant, c299G>C (p.Arg100Pro, NM_002382.5) that the bioinformatics prediction programs defined as noxious and causative of pathology. Conclusion: This report represents the first description of a co-occurrence of multiple composite PCC-GN and neuroblastic tumors. The long timeline of the presentation of the NENs/neuroblastic tumors from infancy to adulthood requires a lifelong follow-up for this patient. Moreover, the importance of this case lies in the presence of a novel MAX gene variant deleterious, harmful, and causative of pathology, confirmed by Sanger sequencing and never been associated before with multiple composite PCC-GN. The present case underlines the importance of precision medicine and molecular diagnoses for hereditary pheochromocytomas and paragangliomas, suggesting that when they occur in early childhood, it is necessary to perform an extensive genetic investigation and a lifelong follow-up. |
format | Online Article Text |
id | pubmed-7249266 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72492662020-06-05 A Novel MAX Gene Mutation Variant in a Patient With Multiple and “Composite” Neuroendocrine–Neuroblastic Tumors Pozza, Carlotta Sesti, Franz Di Dato, Carla Sbardella, Emilia Pofi, Riccardo Schiavi, Francesca Bonifacio, Vincenzo Isidori, Andrea M. Faggiano, Antongiulio Lenzi, Andrea Giannetta, Elisa Front Endocrinol (Lausanne) Endocrinology Introduction: Pheochromocytomas (PCCs), paragangliomas (PGLs), ganglioneuroblastomas (GNBs), and ganglioneuromas (GNs) are neuroendocrine neoplasms (NENs) that were thought to share a common embryologic origin from neural crest cells. However, they rarely occur concurrently and recurrently. We describe the case of a 40-years-old woman with “composite PCC-GN” and multiple NENs and neuroblastic tumors. Case presentation: The patient was first referred to our department at the age of 15 years for paroxysmal hypertension, headache, sweating, and watery diarrhea. Her personal history included the diagnosis of a pelvic GNB with lumbar–aortic lymph node metastases at 11 months. Her family history was positive for cerebral glioblastoma multiforme (father). An abdominal ultrasound showed a right adrenal mass that histologically was a “composite adrenal PCC-GN.” The symptoms disappeared after surgery. At the age of 20 years, the symptoms returned: computed tomography (CT) and 131I-metaiodobenzylguanidine (MIBG) scintigraphy showed an inter-aortocaval mass, found histologically to be an inter-aortocaval PGL. Her symptoms reappeared again at 28 years: CT and magnetic resonance imaging revealed four left adrenal gland nodules, found histologically to be multifocal PCCs with some atypia. Genetic screening for VHL, RET, NF1, Tp53, SDHD, SDHB, SDHC, SDHAF2, SDHAF3, SDHA, and TMEM127 was negative. Mutational analysis of the MAX gene revealed the presence of a novel heterozygous variant, c299G>C (p.Arg100Pro, NM_002382.5) that the bioinformatics prediction programs defined as noxious and causative of pathology. Conclusion: This report represents the first description of a co-occurrence of multiple composite PCC-GN and neuroblastic tumors. The long timeline of the presentation of the NENs/neuroblastic tumors from infancy to adulthood requires a lifelong follow-up for this patient. Moreover, the importance of this case lies in the presence of a novel MAX gene variant deleterious, harmful, and causative of pathology, confirmed by Sanger sequencing and never been associated before with multiple composite PCC-GN. The present case underlines the importance of precision medicine and molecular diagnoses for hereditary pheochromocytomas and paragangliomas, suggesting that when they occur in early childhood, it is necessary to perform an extensive genetic investigation and a lifelong follow-up. Frontiers Media S.A. 2020-05-19 /pmc/articles/PMC7249266/ /pubmed/32508744 http://dx.doi.org/10.3389/fendo.2020.00234 Text en Copyright © 2020 Pozza, Sesti, Di Dato, Sbardella, Pofi, Schiavi, Bonifacio, Isidori, Faggiano, Lenzi and Giannetta. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Pozza, Carlotta Sesti, Franz Di Dato, Carla Sbardella, Emilia Pofi, Riccardo Schiavi, Francesca Bonifacio, Vincenzo Isidori, Andrea M. Faggiano, Antongiulio Lenzi, Andrea Giannetta, Elisa A Novel MAX Gene Mutation Variant in a Patient With Multiple and “Composite” Neuroendocrine–Neuroblastic Tumors |
title | A Novel MAX Gene Mutation Variant in a Patient With Multiple and “Composite” Neuroendocrine–Neuroblastic Tumors |
title_full | A Novel MAX Gene Mutation Variant in a Patient With Multiple and “Composite” Neuroendocrine–Neuroblastic Tumors |
title_fullStr | A Novel MAX Gene Mutation Variant in a Patient With Multiple and “Composite” Neuroendocrine–Neuroblastic Tumors |
title_full_unstemmed | A Novel MAX Gene Mutation Variant in a Patient With Multiple and “Composite” Neuroendocrine–Neuroblastic Tumors |
title_short | A Novel MAX Gene Mutation Variant in a Patient With Multiple and “Composite” Neuroendocrine–Neuroblastic Tumors |
title_sort | novel max gene mutation variant in a patient with multiple and “composite” neuroendocrine–neuroblastic tumors |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249266/ https://www.ncbi.nlm.nih.gov/pubmed/32508744 http://dx.doi.org/10.3389/fendo.2020.00234 |
work_keys_str_mv | AT pozzacarlotta anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT sestifranz anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT didatocarla anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT sbardellaemilia anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT pofiriccardo anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT schiavifrancesca anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT bonifaciovincenzo anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT isidoriandream anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT faggianoantongiulio anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT lenziandrea anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT giannettaelisa anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT pozzacarlotta novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT sestifranz novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT didatocarla novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT sbardellaemilia novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT pofiriccardo novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT schiavifrancesca novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT bonifaciovincenzo novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT isidoriandream novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT faggianoantongiulio novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT lenziandrea novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors AT giannettaelisa novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors |